Laurus Lab TLD

Laurus Lab TLD (2)

Overview Laurus Lab TLD (2) is a fixed-dose combination antiretroviral therapy (ART) that includes Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), and Dolutegravir (DTG). It is designed for the treatment of HIV-1 infection and is effective in both treatment-naïve and experienced patients. This medication is widely used due to its high efficacy, safety profile, and the convenience of once-daily dosing.

Composition

1. Tenofovir disoproxil fumarate (300 mg): An NRTI that inhibits HIV replication by preventing the reverse transcriptase enzyme from converting viral RNA into DNA.
2. Lamivudine (300 mg): Another NRTI that works similarly to tenofovir, providing a synergistic effect in inhibiting HIV replication.
3. Dolutegravir (50 mg): An integrase inhibitor that prevents the integration of viral DNA into the host genome, a crucial step for viral replication.

Benefits

• Effective Viral Suppression: Significantly reduces the viral load in the body, aiding in the restoration and preservation of the immune system.
• Once-Daily Regimen: Simplifies adherence, making it easier for patients to consistently take their medication.
• Well-Tolerated: Lower incidence of severe side effects compared to older regimens, with common side effects being generally mild.

Common Side Effects

• Insomnia: Some patients may experience difficulty sleeping.
• Headache and Dizziness: These are common but usually mild.
• Nausea: May occur, particularly at the beginning of treatment.
• Fatigue: Some users may feel unusually tired.

Usage Considerations

• Administration: Can be taken with or without food. However, caution is advised when taking with supplements containing calcium, magnesium,